The influx of innovative pharmaceutical companies has intensified, how to break the situation?

Recently, major listed pharmaceutical companies have intensively disclosed their 2021 performance forecasts
.
According to incomplete statistics, as of February 8, 2022, a total of 243 medical companies in the A-share market have released their 2021 performance forecasts, most of which are expected to increase, but there are also 60 companies that are pre-loss, accounting for about 25%
.
Among these pre-loss enterprises, the first and continuing loss enterprises each account for half
.
It is worth noting that among the pre-loss companies, there are 13 innovative drug companies
.
Including BeiGene, Frontier Bio, Shanghai Yizhong, Asieris, Junshi Bio, Shutaishen, Shenzhou Cell, Zejing Pharmaceutical, etc.
, all suffered consecutive losses
.
Among them, BeiGene has a higher pre-loss
.
According to the prospectus released by BeiGene on November 16, 2021, it is expected that the company's operating income in 2021 will be 6.
85 billion yuan to 8.
02 billion yuan, and the net profit attributable to the parent will be a loss of 8.
542 billion yuan to 11.
012 million yuan
.
It is understood that the huge investment in research and development is one of the main reasons for its continuous loss
.
According to data, from 2018 to the first half of 2021, BeiGene has invested more than 24.
2 billion yuan in research and development expenses
.
Among them, the research and development expenses in the first three quarters of 2021 have reached 6.
52 billion yuan, and the research and development expense rate is 104.
7%
.
However, thanks to continuous investment in innovative research and development, BeiGene has also approved 3 products for the market, namely the BTK inhibitor zanubrutinib, PD-1 monoclonal antibody tislelizumab and PARP inhibitor Dosage Pamidalide
.
The industry expects that with the continuous increase in R&D investment in the future, BeiGene's innovation achievements will continue to appear
.
However, it should be noted that the industry has also proposed that with the continuous emergence of innovative achievements, many products will also face more intense market competition after they are launched
.
Taking BTK inhibitors as an example, there are currently 5 BTK inhibitors on the market, 3 of which have been listed in China, namely AbbVie and Johnson & Johnson's ibrutinib, BeiGene's zanubrutinib, and InnoCare.
Orelabrutinib
.
In addition to the above companies, a total of 6 companies have deployed BTK inhibitors, most of which are in Phase 1 and Phase 2 clinical trials
.
It should be noted that industry analysts believe that the continuous increase in R&D investment and product competition that BeiGene is currently facing are actually the problems faced by a number of domestic innovative drug companies
.
According to data, from 2016 to 2021, under the background of accelerated innovation of pharmaceutical companies, 66 domestically produced Class 1 new drugs have been launched in China;
.
But judging from the targets involved in new drugs in the past 6 years, 41% of new drugs focused on the top 6% of popular targets
.
As a result, the industry predicts that as pharmaceutical companies continue to increase investment in research and development, some tracks will become more crowded, and competition for many products will become more intense
.
In this context, industry analysts believe that pharmaceutical companies should try their best to realize the clinical value of product differentiation, strive to realize the value of innovative drugs in the international market, improve enterprise management capabilities, and develop scientific sales model selection and commercialization promotion strategies.
Better avoid involution and achieve higher quality development
.